LC/MS, LC/MS/MS, LC/Orbitrap, LC/HRMS
IndustriesPharma & Biopharma
ManufacturerThermo Fisher Scientific
Importance of the Topic
Recent advances in therapeutic oligonucleotides, including antisense oligonucleotides (ASOs) and mRNA, have created a pressing need for robust analytical workflows. Accurate impurity profiling and characterization are essential to ensure safety, efficacy and regulatory compliance. Traditional ion-pairing reagents and HFIP pose challenges for method development, instrument maintenance and GLP compliance. A streamlined, ion-pair-free LC-HRMS approach offers significant advantages for pharmaceutical quality control and research.
Objectives and Study Overview
This work demonstrates a fully automated, GLP-compliant method to analyze ASO purity without using HFIP or amine-based ion-pairing agents. Using Spinraza (Nusinersen) as a model, the study aims to achieve high sensitivity, reliable impurity identification and quantitative performance by combining high-pH reversed-phase UHPLC, high-resolution mass spectrometry and advanced data handling in a single chromatography control platform.
Methodology and Instrumentation
The analytical workflow comprises:
- Reversed-phase UHPLC on a DNAPac RP column (4 μm, 2.1 × 100 mm) using a Thermo Scientific Vanquish Flex Binary UHPLC system with an ammonium acetate mobile phase at elevated pH.
- High-resolution MS detection on a Thermo Scientific Orbitrap Exploris instrument, controlled by Chromeleon 7.3.2 software.
- Data processing with Chromeleon’s 64-bit reporting engine, featuring automated deconvolution, extracted ion chromatogram (XIC) generation, impurity annotation and flexible report generation.
Key Results and Discussion
- Source optimization minimized adduct formation and in-source fragmentation, leading to cleaner mass spectra and reliable impurity assignments.
- Chromatographic separation delivered sharp peaks for the full-length product and related impurities, with high signal-to-noise ratios.
- Charge state profiling enabled discrimination between true impurities and spectral artefacts; deconvoluted spectra and targeted XIC quantitation produced comparable purity results.
- Elimination of HFIP and ion-pair reagents allowed gentler source conditions, reducing maintenance burdens and improving reproducibility.
Benefits and Practical Applications
- Comprehensive ASO purity assessment in a single run, supporting method development and QC release.
- Fully GLP-compliant data handling and reporting streamline regulatory submissions.
- Removal of toxic or corrosive mobile-phase additives enhances laboratory safety and instrument longevity.
- Automated workflows reduce user intervention and turnaround times in routine analysis.
Future Trends and Opportunities
- Broader adoption of HFIP-free, high-pH reversed-phase methods for diverse oligonucleotide modalities.
- Integration of triple quadrupole and high-resolution MS platforms for targeted quantitation strategies.
- Advanced data analytics, machine learning and collaborative laboratory informatics to improve impurity prediction and method transfer.
- Expansion of automated, GLP-compliant reporting frameworks to support large-scale oligonucleotide production and quality assurance.
Conclusion
The presented HFIP-free, ion-pair-free RP-LC HRAM MS workflow, combined with Chromeleon’s advanced deconvolution and XIC capabilities, offers a powerful, fully automated solution for ASO purity analysis. The method meets GLP requirements, simplifies instrument operation and delivers reliable, high-confidence impurity data critical for therapeutic oligonucleotide development and quality control.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.